Presented By: Benjamin Schmid and Peter Reinhardt

Speaker Biography: Dr. Benjamin Schmid received his PhD in Biochemistry in 2013 at the Department for Neurodegenerative Diseases, Eberhard Karls University in Tuebingen, Germany. During his PhD, he worked on the development of new disease models for Parkinson's disease using iPS cells in combination with genome-editing techniques.
Dr. Peter Reinhardt received his Ph.D from the Department of Cell and Developmental Biology at the ax-Planck-Institute for Molecular Biomedicine, Münster, Germany where he continued his research as a Postdoctoral Fellow in the Group for Stem Cells and Neurodegeneration.

Webinar: Tools & Strategies for Implementing iPSC-based Cell Models for Neurodegenerative Disease Drug Discovery

Webinar Abstract: The ability to derive induced pluripotent stem cells (iPSCs) from differentiated cell types such as fibroblasts, has revolutionized drug discovery for many disease areas including neurodegenerative disease. Reprogramming patient-derived cells (e.g fibroblasts, PBMCs) into stem cells allows researchers to capture more relevant disease models harboring genotypes for neurodegenerative disease with complex pathology.
By using human iPSCs, it is possible to establish uniform and scalable cell models for drug discovery, without the limitations or invasive procedures associated with using primary cells, or the uncertain translatability of animal models. In combination with precision gene editing through e.g CRISPR/Cas9 technology and directed differentiation of iPSCs to different neuronal cell types, these disease models provide an invaluable tool for accelerating drug discovery.

Labroots on Social:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Instagram: [ Ссылка ]
Pinterest: [ Ссылка ]
SnapChat: labroots_inc

свернуть